Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

This investor's weighing up a couple of world-class companies for his Stocks and Shares ISA after the US election sparked a sell-off.

European mega-caps trail US 'Magnificent Seven' amid lack of artificial intelligence gains, while also facing China's ...

The move intensifies the competition with Eli Lilly, which secured approval for its weight loss drug in China in July but has ...

Denmark has pledged an additional 1 billion DKK to purchase military equipment from Ukraine’s defense industry. Prime Minister Mette Frederiksen announced the donation during a visit to Ukraine, ...

The number of public electric vehicle (EV) charging points in Denmark has grown by over 70 percent in the past year, according to new data from Mobility Denmark. In October 2024, there were 27,298 ...

Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It ...

The first European company is in 25th place – Denmark’s Novo Nordisk, famed for its manufacture of Ozempic ... Germany’s car ...

China has recovered slightly from last year ... up from just 33% last year. Earlier in November, Novo Nordisk's Wegovy weight ...

The global GLP-1 analogues market size was assessed at USD 46.70 billion in 2024. The market is expected to flourish and grow from USD 56.62 billion in 2025 to USD 322.85 billion by 2034, denoting a ...